

Molecular Classification of Biological Phenotypes

Esfandiar Haghverdi

School of Informatics

November 13, 2008

Outline

- ▶ Introduction
- ▶ Class Comparison
- ▶ Class Discovery
- ▶ Class Prediction
- ▶ Example
- ▶ Biological states and state modulation
- ▶ Chemical Genomics
- ▶ Toxicogenomics
- ▶ Software Tools
- ▶ Ideas

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.
- ▶ Extract meaningful information about the system being studied from gene expression data.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.
- ▶ Extract meaningful information about the system being studied from gene expression data.
- ▶ The work is motivated by recent progress in cancer genomics.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.
- ▶ Extract meaningful information about the system being studied from gene expression data.
- ▶ The work is motivated by recent progress in cancer genomics.
- ▶ This overview is by no means comprehensive.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.
- ▶ Extract meaningful information about the system being studied from gene expression data.
- ▶ The work is motivated by recent progress in cancer genomics.
- ▶ This overview is by no means comprehensive.
- ▶ There is no one-size-fits-all solution for the analysis and interpretation of genome wide data.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.
- ▶ Extract meaningful information about the system being studied from gene expression data.
- ▶ The work is motivated by recent progress in cancer genomics.
- ▶ This overview is by no means comprehensive.
- ▶ There is no one-size-fits-all solution for the analysis and interpretation of genome wide data.
- ▶ Many analysis options are available at all phases of analysis.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.
- ▶ Extract meaningful information about the system being studied from gene expression data.
- ▶ The work is motivated by recent progress in cancer genomics.
- ▶ This overview is by no means comprehensive.
- ▶ There is no one-size-fits-all solution for the analysis and interpretation of genome wide data.
- ▶ Many analysis options are available at all phases of analysis.
- ▶ An understanding of both **biology** and the **computational methods** is essential.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.
- ▶ Extract meaningful information about the system being studied from gene expression data.
- ▶ The work is motivated by recent progress in cancer genomics.
- ▶ This overview is by no means comprehensive.
- ▶ There is no one-size-fits-all solution for the analysis and interpretation of genome wide data.
- ▶ Many analysis options are available at all phases of analysis.
- ▶ An understanding of both **biology** and the **computational methods** is essential.
- ▶ Complex mathematical methods do **not** necessarily perform better than simpler ones.

Introduction

- ▶ Welcome to Genomics Data Mining (GDM) working group.
- ▶ Meetings will be bi-weekly starting today.
- ▶ Extract meaningful information about the system being studied from gene expression data.
- ▶ The work is motivated by recent progress in cancer genomics.
- ▶ This overview is by no means comprehensive.
- ▶ There is no one-size-fits-all solution for the analysis and interpretation of genome wide data.
- ▶ Many analysis options are available at all phases of analysis.
- ▶ An understanding of both **biology** and the **computational methods** is essential.
- ▶ Complex mathematical methods do **not** necessarily perform better than simpler ones.
- ▶ Prepackaged analysis tools are **not** a good substitute for collaboration with computational/statistical scientists on complex problems.

- ▶ **Gene expression signatures:** One can rationally distill a list of genes from an unbiased global scan of gene-expression changes observed across a carefully selected sample set.

- ▶ **Gene expression signatures:** One can rationally distill a list of genes from an unbiased global scan of gene-expression changes observed across a carefully selected sample set.
- ▶ Biological states can be characterized by gene expression signatures.

- ▶ **Gene expression signatures:** One can rationally distill a list of genes from an unbiased global scan of gene-expression changes observed across a carefully selected sample set.
- ▶ Biological states can be characterized by gene expression signatures.
- ▶ We can use gene expression signatures as surrogates for biological states.

- ▶ **Gene expression signatures:** Molecular Classification of Cancer, T.R. Golub et al., *Science* **286**, 531, 1999.

- ▶ **Gene expression signatures:** Molecular Classification of Cancer, T.R. Golub et al., *Science* **286**, 531, 1999.
- ▶ **GSEA:** Gene Set Enrichment Analysis, A. Subramanian et al., *PNAS*, **102**, 2005.

- ▶ **Gene expression signatures:** Molecular Classification of Cancer, T.R. Golub et al., *Science* **286**, 531, 1999.
- ▶ **GSEA:** Gene Set Enrichment Analysis, A. Subramanian et al., *PNAS*, **102**, 2005.
- ▶ **GE-HTS:** Gene Expression-based High-throughput Screening, K. Stegmaier et al., *Nature genetics* **36**, 257, 2004.

- ▶ **Gene expression signatures:** Molecular Classification of Cancer, T.R. Golub et al., *Science* **286**, 531, 1999.
- ▶ **GSEA:** Gene Set Enrichment Analysis, A. Subramanian et al., *PNAS*, **102**, 2005.
- ▶ **GE-HTS:** Gene Expression-based High-throughput Screening, K. Stegmaier et al., *Nature genetics* **36**, 257, 2004.
- ▶ **Connectivity Map:** The Connectivity Map, J. Lamb et al., *Science* **313**, 1929, 2006.

Class Comparison

- ▶ *Goal:* Identify differentially expressed genes.

Class Comparison

- ▶ *Goal:* Identify differentially expressed genes.
- ▶ *Methods:*
 - ▶ Calculate a test statistic (t -test, ANOVA F statistic, non-parametric rank-based, . . .)
 - ▶ Determine the significance of the observed value for test statistic.
 - ▶ **Normality, equal variance, multiple testing, FWER vs FDR**

Class Comparison

- ▶ *Goal:* Identify differentially expressed genes.
- ▶ *Methods:*
 - ▶ Calculate a test statistic (t -test, ANOVA F statistic, non-parametric rank-based, . . .)
 - ▶ Determine the significance of the observed value for test statistic.
 - ▶ **Normality, equal variance, multiple testing, FWER vs FDR**
- ▶ *Issues:*
 - ▶ Two or more experimental conditions
 - ▶ Conditions may be independent or related (time series)
 - ▶ Many different combinations of experimental variables
 - ▶ Replication, to estimate variability, to identify biologically reproducible changes
 - ▶ How to incorporate estimates of variation (model-based methods)

Opportunities:

Time-series analysis:

- ▶ Regulatory pathway inference
- ▶ Yeast cell cycle (Fourier transform, ...)
- ▶ Model organism (e.g., *Drosophila*, *Daphnia*) development
- ▶ Analysis of samples (cells) exposed to different doses of the same drug
- ▶ Analysis of expression patterns from related bacterial strains

Class Discovery

- ▶ *Goal:* Identify meaningful patterns in the data, (aka. Unsupervised learning.)

Class Discovery

- ▶ *Goal:* Identify meaningful patterns in the data, (aka. Unsupervised learning.)
- ▶ *Methods:*

Class Discovery

- ▶ *Goal:* Identify meaningful patterns in the data, (aka. Unsupervised learning.)
- ▶ *Methods:*
 - ▶ *Dimensionality reduction methods:* Most of the variation in data can be explained by a smaller number of transformed variables.

Class Discovery

- ▶ *Goal:* Identify meaningful patterns in the data, (aka. Unsupervised learning.)
- ▶ *Methods:*
 - ▶ *Dimensionality reduction methods:* Most of the variation in data can be explained by a smaller number of transformed variables.
 - ▶ For example: SVD, PCA, MDS,

- ▶ *Goal:* Identify meaningful patterns in the data, (aka. Unsupervised learning.)
- ▶ *Methods:*
 - ▶ *Dimensionality reduction methods:* Most of the variation in data can be explained by a smaller number of transformed variables.
 - ▶ For example: SVD, PCA, MDS,
 - ▶ *Clustering:* Data can be grouped into groups of similar points based on some similarity measure.
 - ▶ Aggregation methods (e.g., HC)
 - ▶ Partitioning or centroid methods (for example, k -means, SOM or Kohonen maps)
 - ▶ Model-based methods (e.g., fitting into some mixture model)
 - ▶ Optimization techniques (within class, between class)

Class Discovery cont'd

Issues:

- ▶ It is unbiased, no a priori assumption.

Class Discovery cont'd

Issues:

- ▶ It is unbiased, no a priori assumption.
- ▶ The structure may not be of clinical or biological interest.

Class Discovery cont'd

Issues:

- ▶ It is unbiased, no a priori assumption.
- ▶ The structure may not be of clinical or biological interest.
- ▶ Should be viewed as a first step in more detailed analysis.

Issues:

- ▶ It is unbiased, no a priori assumption.
- ▶ The structure may not be of clinical or biological interest.
- ▶ Should be viewed as a first step in more detailed analysis.
- ▶ There is no single best way to evaluate a clustering method or a cluster.

Issues:

- ▶ It is unbiased, no a priori assumption.
- ▶ The structure may not be of clinical or biological interest.
- ▶ Should be viewed as a first step in more detailed analysis.
- ▶ There is no single best way to evaluate a clustering method or a cluster.
- ▶ How to evaluate clustering methods?

Issues:

- ▶ It is unbiased, no a priori assumption.
- ▶ The structure may not be of clinical or biological interest.
- ▶ Should be viewed as a first step in more detailed analysis.
- ▶ There is no single best way to evaluate a clustering method or a cluster.
- ▶ How to evaluate clustering methods?
- ▶ There is no single best clustering method for a data set.

Issues:

- ▶ It is unbiased, no a priori assumption.
- ▶ The structure may not be of clinical or biological interest.
- ▶ Should be viewed as a first step in more detailed analysis.
- ▶ There is no single best way to evaluate a clustering method or a cluster.
- ▶ How to evaluate clustering methods?
- ▶ There is no single best clustering method for a data set.
- ▶ Some desirable properties maybe: Stability (reliability), predictive power, reduction power, ...

Issues:

- ▶ It is unbiased, no a priori assumption.
- ▶ The structure may not be of clinical or biological interest.
- ▶ Should be viewed as a first step in more detailed analysis.
- ▶ There is no single best way to evaluate a clustering method or a cluster.
- ▶ How to evaluate clustering methods?
- ▶ There is no single best clustering method for a data set.
- ▶ Some desirable properties maybe: Stability (reliability), predictive power, reduction power, ...
- ▶ How to choose the number of clusters (Gordon, repeated sampling, gap statistic, ...)

Opportunities:

- ▶ Stochastic clustering (e.g., NMF)

Opportunities:

- ▶ Stochastic clustering (e.g., NMF)
- ▶ Techniques from statistical physics (e.g., Deterministic Annealing)

Opportunities:

- ▶ Stochastic clustering (e.g., NMF)
- ▶ Techniques from statistical physics (e.g., Deterministic Annealing)
- ▶ Spectral methods (e.g., Diffusion maps on graphs)

Opportunities:

- ▶ Stochastic clustering (e.g., NMF)
- ▶ Techniques from statistical physics (e.g., Deterministic Annealing)
- ▶ Spectral methods (e.g., Diffusion maps on graphs)
- ▶ Geometric methods (e.g., Diffusion maps on manifolds)


Opportunities:

- ▶ Stochastic clustering (e.g., NMF)
- ▶ Techniques from statistical physics (e.g., Deterministic Annealing)
- ▶ Spectral methods (e.g., Diffusion maps on graphs)
- ▶ Geometric methods (e.g., Diffusion maps on manifolds)
- ▶ Information theoretic methods

Opportunities:

- ▶ Stochastic clustering (e.g., NMF)
- ▶ Techniques from statistical physics (e.g., Deterministic Annealing)
- ▶ Spectral methods (e.g., Diffusion maps on graphs)
- ▶ Geometric methods (e.g., Diffusion maps on manifolds)
- ▶ Information theoretic methods
- ▶ Statistical theory of clustering (Cf. comparing clustering methods)

Class Discovery Methodology



Class Prediction

- ▶ *Goal:* Design an accurate classifier (predictor) under the guidance of a supervisor, (aka. Supervised learning problem.)
E.g., predicting cancer (sub)types, clinical outcomes, etc.

Class Prediction

- ▶ *Goal:* Design an accurate classifier (predictor) under the guidance of a supervisor, (aka. Supervised learning problem.)
E.g., predicting cancer (sub)types, clinical outcomes, etc.
- ▶ *Methods:*
 - ▶ Linear and quadratic discriminant analysis
 - ▶ Weighted voting
 - ▶ Shrunken centroids
 - ▶ k -NN
 - ▶ Neural nets
 - ▶ SVM
 - ▶ Decision tree classifiers
 - ▶ Naive Bayes
 - ▶ Bagging and boosting (combining classifiers)

Issues:

- ▶ features \gg samples

Issues:

- ▶ features \gg samples
- ▶ Overfitting (modeling the training data too exactly)

Issues:

- ▶ features \gg samples
- ▶ Overfitting (modeling the training data too exactly)
- ▶ High level of noise

Issues:

- ▶ features \gg samples
- ▶ Overfitting (modeling the training data too exactly)
- ▶ High level of noise
- ▶ Which method to choose?

Issues:

- ▶ features \gg samples
- ▶ Overfitting (modeling the training data too exactly)
- ▶ High level of noise
- ▶ Which method to choose?
 - ▶ Careful with comparisons

Issues:

- ▶ features \gg samples
- ▶ Overfitting (modeling the training data too exactly)
- ▶ High level of noise
- ▶ Which method to choose?
 - ▶ Careful with comparisons
 - ▶ Some trends emerge (e.g, Diagonal LD does better than Fisher's LD, k -NN performs better after gene filtering, combined methods do better, simpler methods do better, ...)

Opportunities:

- ▶ Theory for method and classifier comparison

Opportunities:

- ▶ Theory for method and classifier comparison
- ▶ Combining knowledge from different methods

Opportunities:

- ▶ Theory for method and classifier comparison
- ▶ Combining knowledge from different methods
- ▶ Incorporating knowledge from complementary sources


Opportunities:

- ▶ Theory for method and classifier comparison
- ▶ Combining knowledge from different methods
- ▶ Incorporating knowledge from complementary sources
- ▶ Boosting the power and rigor of analysis


Opportunities:

- ▶ Theory for method and classifier comparison
- ▶ Combining knowledge from different methods
- ▶ Incorporating knowledge from complementary sources
- ▶ Boosting the power and rigor of analysis
- ▶ Subpattern discovery, Califano et al. 99

Marker Selection Methodology



Class Prediction Methodology



Example (Golub et al. 1999)




Figure 2-8a The Biology of Cancer (© Garland Science 2007)





Figure 2-8b The Biology of Cancer (© Garland Science 2007)

ALL vs AML (The Biology of Cancer, R. Weinberg)

Compare to this!!



Normal kidney vs Renal cell carcinoma.

Example cont'd

- ▶ **Sample:** 38 bone marrow samples (27 ALL, 11 AML).
6817 genes

Example cont'd

- ▶ **Sample:** 38 bone marrow samples (27 ALL, 11 AML).
6817 genes
- ▶ **Test statistic:** $SNR = \frac{\mu_1 - \mu_2}{\sigma_1 + \sigma_2}$ to determine gene-class correlation

Example cont'd

- ▶ **Sample:** 38 bone marrow samples (27 ALL, 11 AML).
6817 genes
- ▶ **Test statistic:** $SNR = \frac{\mu_1 - \mu_2}{\sigma_1 + \sigma_2}$ to determine gene-class correlation
- ▶ **Significance test:** Permutation test (nhood analysis)

Example cont'd

- ▶ **Sample:** 38 bone marrow samples (27 ALL, 11 AML).
6817 genes
- ▶ **Test statistic:** $SNR = \frac{\mu_1 - \mu_2}{\sigma_1 + \sigma_2}$ to determine gene-class correlation
- ▶ **Significance test:** Permutation test (nhood analysis)
- ▶ **Signature:** 50 informative genes are selected

Example cont'd

- ▶ **Sample:** 38 bone marrow samples (27 ALL, 11 AML). 6817 genes
- ▶ **Test statistic:** $SNR = \frac{\mu_1 - \mu_2}{\sigma_1 + \sigma_2}$ to determine gene-class correlation
- ▶ **Significance test:** Permutation test (nhood analysis)
- ▶ **Signature:** 50 informative genes are selected
- ▶ **Prediction:** Given a new sample each informative gene casts a weighted vote, the votes are then summed to determine the winning class and to define the $0 < PS < 1$ (prediction strength) which needs to be above 0.3 for each decisive vote.

Example cont'd

- ▶ **Sample:** 38 bone marrow samples (27 ALL, 11 AML). 6817 genes
- ▶ **Test statistic:** $SNR = \frac{\mu_1 - \mu_2}{\sigma_1 + \sigma_2}$ to determine gene-class correlation
- ▶ **Significance test:** Permutation test (nhood analysis)
- ▶ **Signature:** 50 informative genes are selected
- ▶ **Prediction:** Given a new sample each informative gene casts a weighted vote, the votes are then summed to determine the winning class and to define the $0 < PS < 1$ (prediction strength) which needs to be above 0.3 for each decisive vote.
- ▶ **Validity of the predictor:** Cross-validation and trying on test data.

In symbols ...

Suppose we have n samples.

- ▶ Gene vector: $v(g) = (e_1, \dots, e_n)$,

In symbols ...

Suppose we have n samples.

- ▶ Gene vector: $v(g) = (e_1, \dots, e_n)$,
- ▶ Class vector: $c = (c_1, \dots, c_n)$: $c_i = 1$ if $i \in AML$, and 0 if $i \in ALL$.

In symbols ...

Suppose we have n samples.

- ▶ Gene vector: $v(g) = (e_1, \dots, e_n)$,
- ▶ Class vector: $c = (c_1, \dots, c_n)$: $c_i = 1$ if $i \in AML$, and 0 if $i \in ALL$.
- ▶ Gene-Class Correlation:
 $P(g, c) = (\mu_1(g) - \mu_2(g)) / (\sigma_1(g) + \sigma_2(g))$ for each gene g .

In symbols ...

Suppose we have n samples.

- ▶ Gene vector: $v(g) = (e_1, \dots, e_n)$,
- ▶ Class vector: $c = (c_1, \dots, c_n)$: $c_i = 1$ if $i \in AML$, and 0 if $i \in ALL$.
- ▶ Gene-Class Correlation:
 $P(g, c) = (\mu_1(g) - \mu_2(g)) / (\sigma_1(g) + \sigma_2(g))$ for each gene g .
- ▶ Nhood: $N_1(c, r) = \{g \mid P(g, c) = r\}$

In symbols ...

Suppose we have n samples.

- ▶ Gene vector: $v(g) = (e_1, \dots, e_n)$,
- ▶ Class vector: $c = (c_1, \dots, c_n)$: $c_i = 1$ if $i \in AML$, and 0 if $i \in ALL$.
- ▶ Gene-Class Correlation:
 $P(g, c) = (\mu_1(g) - \mu_2(g)) / (\sigma_1(g) + \sigma_2(g))$ for each gene g .
- ▶ Nhood: $N_1(c, r) = \{g \mid P(g, c) = r\}$
- ▶ Permutation test: compare with $N_1(c^*, r)$, for 400 permutations.

In symbols ...

Suppose we have n samples.

- ▶ Gene vector: $v(g) = (e_1, \dots, e_n)$,
- ▶ Class vector: $c = (c_1, \dots, c_n)$: $c_i = 1$ if $i \in AML$, and 0 if $i \in ALL$.
- ▶ Gene-Class Correlation:
 $P(g, c) = (\mu_1(g) - \mu_2(g)) / (\sigma_1(g) + \sigma_2(g))$ for each gene g .
- ▶ Nhood: $N_1(c, r) = \{g \mid P(g, c) = r\}$
- ▶ Permutation test: compare with $N_1(c^*, r)$, for 400 permutations.
- ▶ Number of informative genes is a free parameter, chosen to be 50: 25 top-most and 25 bottom-most.

In symbols ...

Suppose we have n samples.

- ▶ Gene vector: $v(g) = (e_1, \dots, e_n)$,
- ▶ Class vector: $c = (c_1, \dots, c_n)$: $c_i = 1$ if $i \in AML$, and 0 if $i \in ALL$.
- ▶ Gene-Class Correlation:
 $P(g, c) = (\mu_1(g) - \mu_2(g)) / (\sigma_1(g) + \sigma_2(g))$ for each gene g .
- ▶ Nhood: $N_1(c, r) = \{g \mid P(g, c) = r\}$
- ▶ Permutation test: compare with $N_1(c^*, r)$, for 400 permutations.
- ▶ Number of informative genes is a free parameter, chosen to be 50: 25 top-most and 25 bottom-most.
 - ▶ Robustness to noise

In symbols ...

Suppose we have n samples.

- ▶ Gene vector: $v(g) = (e_1, \dots, e_n)$,
- ▶ Class vector: $c = (c_1, \dots, c_n)$: $c_i = 1$ if $i \in AML$, and 0 if $i \in ALL$.
- ▶ Gene-Class Correlation:
 $P(g, c) = (\mu_1(g) - \mu_2(g)) / (\sigma_1(g) + \sigma_2(g))$ for each gene g .
- ▶ Nhood: $N_1(c, r) = \{g \mid P(g, c) = r\}$
- ▶ Permutation test: compare with $N_1(c^*, r)$, for 400 permutations.
- ▶ Number of informative genes is a free parameter, chosen to be 50: 25 top-most and 25 bottom-most.
 - ▶ Robustness to noise
 - ▶ Ease of applicability.

Predictor Design:

- ▶ $v_g = a_g(x_g - b_g)$ where $a_g = P(g, c)$,
 $b_g = [\mu_1(g) + \mu_2(g)]/2$,

Predictor Design:

- ▶ $v_g = a_g(x_g - b_g)$ where $a_g = P(g, c)$,
 $b_g = [\mu_1(g) + \mu_2(g)]/2$,
- ▶ x_g normalized log expression level of gene g in sample x

Predictor Design:

- ▶ $v_g = a_g(x_g - b_g)$ where $a_g = P(g, c)$,
 $b_g = [\mu_1(g) + \mu_2(g)]/2$,
- ▶ x_g normalized log expression level of gene g in sample x
- ▶ $v_g \geq 0$ means g votes for class 1 (AML) and $v_g < 0$ means g votes for class 2 (ALL).

Predictor Design:

- ▶ $v_g = a_g(x_g - b_g)$ where $a_g = P(g, c)$,
 $b_g = [\mu_1(g) + \mu_2(g)]/2$,
- ▶ x_g normalized log expression level of gene g in sample x
- ▶ $v_g \geq 0$ means g votes for class 1 (AML) and $v_g < 0$ means g votes for class 2 (ALL).
- ▶ $V_1 = \sum_{g \in IG} v_g$ for $v_g \geq 0$, and

Predictor Design:

- ▶ $v_g = a_g(x_g - b_g)$ where $a_g = P(g, c)$,
 $b_g = [\mu_1(g) + \mu_2(g)]/2$,
- ▶ x_g normalized log expression level of gene g in sample x
- ▶ $v_g \geq 0$ means g votes for class 1 (AML) and $v_g < 0$ means g votes for class 2 (ALL).
- ▶ $V_1 = \sum_{g \in IG} v_g$ for $v_g \geq 0$, and
- ▶ $V_2 = \sum_{g \in IG} |v_g|$ for $v_g < 0$.

Predictor Design:

- ▶ $v_g = a_g(x_g - b_g)$ where $a_g = P(g, c)$,
 $b_g = [\mu_1(g) + \mu_2(g)]/2$,
- ▶ x_g normalized log expression level of gene g in sample x
- ▶ $v_g \geq 0$ means g votes for class 1 (AML) and $v_g < 0$ means g votes for class 2 (ALL).
- ▶ $V_1 = \sum_{g \in IG} v_g$ for $v_g \geq 0$, and
- ▶ $V_2 = \sum_{g \in IG} |v_g|$ for $v_g < 0$.
- ▶ $PS = (V_{win} - V_{lose}) / (V_{win} + V_{lose})$

Predictor Design:

- ▶ $v_g = a_g(x_g - b_g)$ where $a_g = P(g, c)$,
 $b_g = [\mu_1(g) + \mu_2(g)]/2$,
- ▶ x_g normalized log expression level of gene g in sample x
- ▶ $v_g \geq 0$ means g votes for class 1 (AML) and $v_g < 0$ means g votes for class 2 (ALL).
- ▶ $V_1 = \sum_{g \in IG} v_g$ for $v_g \geq 0$, and
- ▶ $V_2 = \sum_{g \in IG} |v_g|$ for $v_g < 0$.
- ▶ $PS = (V_{win} - V_{lose}) / (V_{win} + V_{lose})$
- ▶ $V_1 > V_2$ with $PS > 0.3$ means $x \in AML$, if $PS \leq 0.3$ then uncertain.

- ▶ Cross-validation: 36 were assigned classes (with 100%) accuracy and 2 were uncertain. Median $PS = 0.77$


- ▶ Cross-validation: 36 were assigned classes (with 100%) accuracy and 2 were uncertain. Median $PS = 0.77$
- ▶ Test data (34 samples): 24 bone marrow and 10 peripheral blood samples, 20 ALL, 14 AML.
Result: 29 predicted with 100% accuracy and 5 uncertain.
Median $PS = 0.73$.

Example cont'd, clustering

- ▶ View each sample as a 6817-dimensional vector and cluster samples.

Example cont'd, clustering

- ▶ View each sample as a 6817-dimensional vector and cluster samples.
- ▶ 2-SOM on 38 samples:
 A_1 : 24 ALL, 1 AML and A_2 : 10 AML, 3 ALL.




4-SOM

- 4-SOM on the same samples:

B_1 : 10 AML, B_2 : 8 T-ALL, 1 B-ALL

B_3 : 5 B-ALL, B_4 : 13 B-ALL, 1 AML.



Example cont'd, clustering

- ▶ How to evaluate clusters to see if they represent true biological structure?

Example cont'd, clustering

- ▶ How to evaluate clusters to see if they represent true biological structure?
- ▶ Idea: true structure implies more accurate predictor.

Example cont'd, clustering

- ▶ How to evaluate clusters to see if they represent true biological structure?
- ▶ Idea: true structure implies more accurate predictor.
- ▶ So design predictors based on clustering classes: leads to merging B_3 and B_4 .

Enrichment Analysis

- ▶ *Goal:* Look at (Gene Set)-Class correlation instead of Gene-Class correlation.

Enrichment Analysis

- ▶ *Goal:* Look at (Gene Set)-Class correlation instead of Gene-Class correlation.
- ▶ *Motivation:*
 - ▶ **Mootha 03:** No single gene is significantly differentially expressed, yet sets of genes might express differentially.
 - ▶ **Subramanian 05:** 1. Robustness to different sites, and 2. Integrating biological knowledge.

Enrichment Analysis

- ▶ *Goal:* Look at (Gene Set)-Class correlation instead of Gene-Class correlation.
- ▶ *Motivation:*
 - ▶ **Mootha 03:** No single gene is significantly differentially expressed, yet sets of genes might express differentially.
 - ▶ **Subramanian 05:** 1. Robustness to different sites, and 2. Integrating biological knowledge.
- ▶ *Methods:*
 - ▶ GSEA (A. Subramanian, PNAS 2005). Lung adenocarcinoma with good/poor outcome. $|S_B \cap S_M| = 12$ and $|S_B \cap S_M \cap S_S| = 1$ whereas S_B in M was NES = 1.9, $p < 0.001$ and S_M in B was NES=2.13, $p < 0.001$.

Enrichment Analysis

- ▶ *Goal:* Look at (Gene Set)-Class correlation instead of Gene-Class correlation.
- ▶ *Motivation:*
 - ▶ **Mootha 03:** No single gene is significantly differentially expressed, yet sets of genes might express differentially.
 - ▶ **Subramanian 05:** 1. Robustness to different sites, and 2. Integrating biological knowledge.
- ▶ *Methods:*
 - ▶ GSEA (A. Subramanian, PNAS 2005). Lung adenocarcinoma with good/poor outcome. $|S_B \cap S_M| = 12$ and $|S_B \cap S_M \cap S_S| = 1$ whereas S_B in M was NES = 1.9, $p < 0.001$ and S_M in B was NES=2.13, $p < 0.001$.
 - ▶ Tibshirani and Efron
 - ▶ R. Gentleman (Bioconductor)
 - ▶ Module maps, a refinement of GSEA, gene set minimization (Segal et al. Nature Genetics, 04,05)

Opportunities:

- ▶ Using BLAST theory to enhance the predictive power.

Opportunities:

- ▶ Using BLAST theory to enhance the predictive power.
- ▶ Random walks on networks.

- ▶ Generating large collections of small molecules and using them to modulate cellular states.

- ▶ Generating large collections of small molecules and using them to modulate cellular states.
- ▶ One approach is to screen different compounds that induce state modulations, using signatures for the states.

- ▶ Generating large collections of small molecules and using them to modulate cellular states.
- ▶ One approach is to screen different compounds that induce state modulations, using signatures for the states.
- ▶ GE-HTS (Stegmaier et al., Nature Genetics, 2004) 1,739 compounds are screened for AML/neutrophil and AML/monocyte terminal cell differentiation.

- ▶ Generating large collections of small molecules and using them to modulate cellular states.
- ▶ One approach is to screen different compounds that induce state modulations, using signatures for the states.
- ▶ GE-HTS (Stegmaier et al., Nature Genetics, 2004) 1,739 compounds are screened for AML/neutrophil and AML/monocyte terminal cell differentiation.
- ▶ *Connectivity Map* (J. Lamb et al., Science 06):
disease – gene – drug.

Issues:

- ▶ Necessary modifications when dealing with more heterogeneous situations, e.g., BC vs Leukemia.

Issues:

- ▶ Necessary modifications when dealing with more heterogeneous situations, e.g., BC vs Leukemia.
- ▶ Choice of cell type

Issues:

- ▶ Necessary modifications when dealing with more heterogeneous situations, e.g., BC vs Leukemia.
- ▶ Choice of cell type
- ▶ Measurement time

Issues:

- ▶ Necessary modifications when dealing with more heterogeneous situations, e.g., BC vs Leukemia.
- ▶ Choice of cell type
- ▶ Measurement time
- ▶ Concentration and treatment duration

Issues:

- ▶ Necessary modifications when dealing with more heterogeneous situations, e.g., BC vs Leukemia.
- ▶ Choice of cell type
- ▶ Measurement time
- ▶ Concentration and treatment duration
- ▶ Analytical methods for detecting relevant signals

- ▶ Identification of potential human and environmental toxicants, and their putative mechanisms of action, through the use of genomics resources.

- ▶ Identification of potential human and environmental toxicants, and their putative mechanisms of action, through the use of genomics resources.
- ▶ Gene expression is altered during toxicity.

- ▶ Identification of potential human and environmental toxicants, and their putative mechanisms of action, through the use of genomics resources.
- ▶ Gene expression is altered during toxicity.
- ▶ Challenge: Given a set of experimental conditions, define the characteristic and specific pattern of gene expression elicited by a given toxicant. (Toxicant signatures!)

- ▶ Identification of potential human and environmental toxicants, and their putative mechanisms of action, through the use of genomics resources.
- ▶ Gene expression is altered during toxicity.
- ▶ Challenge: Given a set of experimental conditions, define the characteristic and specific pattern of gene expression elicited by a given toxicant. (Toxicant signatures!)
- ▶ Given a model organism:
Known toxicants → signatures → database → determine the action mechanism of an unknown toxicant.

- ▶ Identification of potential human and environmental toxicants, and their putative mechanisms of action, through the use of genomics resources.
- ▶ Gene expression is altered during toxicity.
- ▶ Challenge: Given a set of experimental conditions, define the characteristic and specific pattern of gene expression elicited by a given toxicant. (Toxicant signatures!)
- ▶ Given a model organism:
Known toxicants → signatures → database → determine the action mechanism of an unknown toxicant.
- ▶ Connectivity Map: gene – toxicant

Issues:

- ▶ Proper definition of signature similarity

Issues:

- ▶ Proper definition of signature similarity
- ▶ Model system selection

Issues:

- ▶ Proper definition of signature similarity
- ▶ Model system selection
- ▶ Dose selection

Issues:

- ▶ Proper definition of signature similarity
- ▶ Model system selection
- ▶ Dose selection
- ▶ Measurement time (Time series analysis?)

Issues:

- ▶ Proper definition of signature similarity
- ▶ Model system selection
- ▶ Dose selection
- ▶ Measurement time (Time series analysis?)
- ▶ Other factors: age, diet, etc

- ▶ Bioconductor

- ▶ Bioconductor
- ▶ BRB ArrayTools (NCI, Richard Simon)

- ▶ Bioconductor
- ▶ BRB ArrayTools (NCI, Richard Simon)
- ▶ GenePattern, includes GeneCluster (Broad Institute)

- ▶ Bioconductor
- ▶ BRB ArrayTools (NCI, Richard Simon)
- ▶ GenePattern, includes GeneCluster (Broad Institute)
- ▶ Connectivity Map (Broad Institute)

- ▶ Bioconductor
- ▶ BRB ArrayTools (NCI, Richard Simon)
- ▶ GenePattern, includes GeneCluster (Broad Institute)
- ▶ Connectivity Map (Broad Institute)
- ▶ Benchmark data sets

- ▶ Bioconductor
- ▶ BRB ArrayTools (NCI, Richard Simon)
- ▶ GenePattern, includes GeneCluster (Broad Institute)
- ▶ Connectivity Map (Broad Institute)
- ▶ Benchmark data sets
- ▶ Local implementations with interface to the tools above

- ▶ Technical improvements at different levels

Some ideas ...

- ▶ Technical improvements at different levels
- ▶ Integrating biological knowledge into the mathematical models (after Random Markov Fields)

Some ideas ...

- ▶ Technical improvements at different levels
- ▶ Integrating biological knowledge into the mathematical models (after Random Markov Fields)
- ▶ New mathematical tools

Some ideas ...

- ▶ Technical improvements at different levels
- ▶ Integrating biological knowledge into the mathematical models (after Random Markov Fields)
- ▶ New mathematical tools
- ▶ Using signatures to infer signalling pathways

Some ideas ...

- ▶ Technical improvements at different levels
- ▶ Integrating biological knowledge into the mathematical models (after Random Markov Fields)
- ▶ New mathematical tools
- ▶ Using signatures to infer signalling pathways
- ▶ Using signatures to improve clustering algorithms

Some ideas ...

- ▶ Technical improvements at different levels
- ▶ Integrating biological knowledge into the mathematical models (after Random Markov Fields)
- ▶ New mathematical tools
- ▶ Using signatures to infer signalling pathways
- ▶ Using signatures to improve clustering algorithms
- ▶ Technology transfer from: Time-series analysis of financial data, VLDB, Theoretical Neuroscience

- ▶ New biologically relevant and important questions:

- ▶ New biologically relevant and important questions:
- ▶ Daphnia based toxicogenomics

- ▶ New biologically relevant and important questions:
- ▶ Daphnia based toxicogenomics
- ▶ Daphnia based ecogenomics

- ▶ New biologically relevant and important questions:
- ▶ Daphnia based toxicogenomics
- ▶ Daphnia based ecogenomics
- ▶ Signatures in developmental stages of model organisms

- ▶ New biologically relevant and important questions:
- ▶ Daphnia based toxicogenomics
- ▶ Daphnia based ecogenomics
- ▶ Signatures in developmental stages of model organisms
- ▶ Time series analysis of environmental effects

- ▶ New biologically relevant and important questions:
- ▶ Daphnia based toxicogenomics
- ▶ Daphnia based ecogenomics
- ▶ Signatures in developmental stages of model organisms
- ▶ Time series analysis of environmental effects
- ▶ Other genomic signatures: DNA methylation patterns, microRNA profiles, metabolite profiles, ...